Beyond Air, Inc. (XAIR) had the kind of Tuesday every biotech dreams about, with shares rocketing over 160% after announcing it's selling most of its autism-focused subsidiary to XTL Biopharmaceuticals Ltd. (XTLB) in a deal that could be worth more than $33 million.
Here's how the math works: Beyond Air is offloading 85% of NeuroNOS Ltd. in exchange for 19.9% of XTL's issued shares, $1 million in cash upfront, and milestone-based contingent payments that could reach $32.5 million if things go well. The deal still needs approval from XTL's shareholders and other standard closing conditions, but it's already reshaping both companies.
For XTL, this is an entry ticket into the autism therapeutics market, which is both enormous and desperately underserved. For Beyond Air, it's a way to unlock value from a subsidiary while staying invested in its success.
The Science Behind NeuroNOS
NeuroNOS wasn't just spun up yesterday. The company was founded by Professor Haitham Amal, a prominent autism researcher from Hebrew University and Harvard, whose work focuses on nitric oxide dysregulation in the brain. That might sound technical, but it's actually a fundamental shift in how we think about treating autism.
Instead of just managing symptoms, NeuroNOS's proprietary small molecules are designed to cross the blood-brain barrier and target the underlying disease mechanisms tied to nitric oxide-related brain disorders. The company has already secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and glioblastoma, which comes with valuable perks like market exclusivity, trial tax credits, and faster regulatory pathways.
What Happens Next
Once the acquisition closes, NeuroNOS will become XTL's flagship platform for autism and neuro-oncology therapies. Both companies say they're committed to advancing NeuroNOS's autism programs as quickly as possible, which makes sense given the market opportunity.
The milestone structure is worth breaking down: Beyond Air could receive up to $5.5 million tied to clinical development progress, from Phase 1 trials all the way through FDA NDA submission. Then there's another $26 million in commercial milestone payments linked to product sales targets if NeuroNOS actually makes it to market.
Steve Lisi, Chairman and CEO of Beyond Air, called the transaction "a pivotal moment for NeuroNOS," saying it validates the groundbreaking science while creating potential value for shareholders by giving NeuroNOS dedicated focus and funding. "We are proud to become significant shareholders in XTL and believe this focused public platform provides NeuroNOS with the resources and commitment needed to advance these critical programs," he added.
Beyond Air shares were trading at $2.31, up 163.70% at the time of the announcement.
